Wockhardt on Monday announced that the US Food and Drug Administration has accepted the New Drug Application (NDA) for its breakthrough, first-in-class antibiotic Zaynich.
Filed on September 30, 2025, the NDA marks a historic milestone—not just for Wockhardt but for the entire Indian pharmaceutical sector. According to the company, this is the first-ever NDA for a New Chemical Entity (NCE) from an Indian pharma company to be filed and accepted by the USFDA.
Wockhardt called the acceptance a transformative achievement that highlights India’s growing innovation capabilities in global drug discovery and development.